Aptahem

Aptahem AB develops aptamer drugs for the treatment of acute life-threatening conditions where coagulation and inflammation interact during the disease process. The company’s lead candidate drug, Apta-1, is under development with the aim of preventing life-threatening organ and tissue damage in patients with sepsis.